Quantcast

Latest Neuroblastoma Stories

2014-10-10 08:24:07

SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. ("MabVax"), a clinical stage oncology drug development company, announced today that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "MBVX" (OTCQB: MBVX.) The previous trading symbol was "TELK" (OTCQB: TELK). J. David Hansen, President and CEO of the Company, said, "We are...

2014-09-25 08:28:30

SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma. In the U.S., the designation carries significant incentives for the development of drugs to treat rare and difficult diseases. The Company is...

2014-07-28 00:21:20

St. Jude Children's Research Hospital study finds that few adult survivors of childhood cancer follow a heart-healthy lifestyle that protects against heart disease, diabetes and other health problems MEMPHIS, Tenn., July 28, 2014 /PRNewswire-USNewswire/ -- A St. Jude Children's Research Hospital study found that 73 percent of adult survivors of childhood cancer more than doubled their risk of developing metabolic syndrome and related health problems by failing to follow a...

2014-06-23 04:20:52

Inhibits Tumor Growth and Vascular Progenitors for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumors CINCINNATI, June 23, 2014 /PRNewswire/ -- Bacterial Robotics, a synthetic microbial biotechnology firm, today announced it secured an oncolytic herpes simplex virus (oHSV) from Nationwide Children's Hospital. The oHSV expresses the human tissue inhibitor metalloproteinases (TIMP3) or firefly luciferase rQT3. The Company is developing unique therapeutic ViruBots(TM). With...

2014-05-15 23:01:53

Advances in Neuroblastoma Research Association Recognizes Physician-Investigator's Progress Against a Challenging Childhood Cancer Philadelphia, Pa (PRWEB) May 15, 2014 The Advances in Neuroblastoma Research Association (ANRA) is conferring its highest honor on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children’s Hospital of Philadelphia (CHOP). Brodeur will receive the ANRA Lifetime Achievement Award tomorrow at the association’s international...

2014-05-08 12:29:37

Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase I study of an immune therapy manufactured at St. Jude Children's Research Hospital MEMPHIS, Tenn., May 8, 2014 /PRNewswire-USNewswire/ -- Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more...

2014-05-05 08:29:42

$2.437 Million, Two-Year Grant Fuels the Sohn Collaborative for Pediatric Cancer Research to Understand and Fight Pediatric Leukemia and Neuroblastoma by Sequencing Genes of 'Outlier' Tumors NEW YORK, May 5, 2014 /PRNewswire-USNewswire/ -- The New York Genome Center (NYGC) and The Sohn Conference Foundation announced today the launch of The Sohn Collaborative for Pediatric Cancer Research, a multi-institutional effort with the goal of fighting two devastating childhood cancers:...

2014-05-04 20:21:32

Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer SYDNEY and COLUMBUS, Ohio, May 4, 2014 /PRNewswire/ -- Researchers and children's cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of...

2014-03-17 08:29:24

NCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful HOUSTON, March 17, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that the first clinical study is underway of a Chimeric Antigen Receptor (CAR) T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient. Researchers from the National Cancer Institute (NCI) have...

2014-02-03 12:29:37

Co-inventors of ATM technology joining company as General Manager of the ATM Program, Scientific Advisory Panel member, respectively SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.